FastWave Medical’s inclusion in the Fierce Medtech 2024 “Fierce 15” list marks a significant recognition of the company’s bold innovation in intravascular lithotripsy (IVL). This prestigious accolade highlights FastWave as one of the most promising private medtech companies, celebrating its disruptive approach and execution strength in the competitive vascular intervention space. The recognition coincides with the company’s latest achievement—securing its eighth U.S. patent for the Artero™ electric IVL (E-IVL) platform, a next-generation solution designed to address long-standing limitations in peripheral artery disease treatment.

FastWave’s Artero™ system stands out by offering circumferential sonic pressure waves at a frequency of 4 Hz—doubling the speed of traditional IVL devices—while maintaining precision, safety, and physician ease-of-use. With its hands-free design, simplified interface, real-time feedback, and lower crossing profile, Artero™ enables efficient modification of arterial calcium even in challenging anatomies. This technology empowers interventional radiologists and vascular specialists with greater procedural control and consistency, ultimately enhancing clinical outcomes and reducing treatment times for patients suffering from peripheral artery disease.

Looking ahead, FastWave’s recognition as a Fierce 15 company sets the stage for accelerated growth, clinical adoption, and continued innovation across its dual-platform strategy. In parallel with its Artero™ advancements, the company is progressing a global feasibility study for Sola™, a novel laser-based coronary IVL system. With a growing patent portfolio and a physician-first design ethos, FastWave is poised to transform the IVL landscape by delivering efficient, intuitive, and scalable technologies that elevate standards of vascular care and meet the evolving needs of clinicians worldwide.